ConvaTec Group PLC (LON:CTEC) Receives Consensus Rating of “Buy” from Analysts

Shares of ConvaTec Group PLC (LON:CTEC) have been given a consensus rating of “Buy” by the six analysts that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is GBX 320.33.

CTEC has been the topic of a number of recent research reports. Berenberg Bank upped their target price on ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a research report on Thursday, January 22nd. UBS Group reaffirmed a “buy” rating and issued a GBX 375 price objective on shares of ConvaTec Group in a report on Friday, November 7th. Peel Hunt reissued an “add” rating and set a GBX 270 target price on shares of ConvaTec Group in a report on Thursday, November 13th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of ConvaTec Group in a research report on Friday, November 14th.

ConvaTec Group Stock Up 0.9%

ConvaTec Group stock opened at GBX 227.43 on Friday. The business’s 50-day simple moving average is GBX 234.18 and its two-hundred day simple moving average is GBX 235.55. The company has a debt-to-equity ratio of 85.32, a quick ratio of 0.96 and a current ratio of 2.26. The company has a market cap of £4.43 billion, a PE ratio of 21.46, a PEG ratio of 0.93 and a beta of 0.64. ConvaTec Group has a fifty-two week low of GBX 209.40 and a fifty-two week high of GBX 311.20.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.